Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation

ConclusionsCollectively, our data indicate that trametinib exhibits efficacy in treating HCC cells via distinct regulation of the MYC and BIM pathways. As such, targeting MEK to block MAPK signaling with trametinib may provide novel treatment opportunities for HCC.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research